Key result
Perioperative antiplatelet use is not associated with 1-year mortality after hip fracture repair.
Why the study?
This study assessed whether perioperative antiplatelet use increases mortality risk among older adults undergoing operative hip fracture repair.
Does perioperative antiplatelet medication use increase the risk of 365-day mortality and perioperative complications in older adults undergoing operative hip fracture repair?
Cohort (n=965)
No
Does perioperative antiplatelet medication use increase the risk of 365-day mortality and perioperative complications in older adults undergoing operative hip fracture repair?
Perioperative continuation or presence of aspirin and/or clopidogrel in older adults undergoing hip fracture surgery does not increase 30-day, 90-day, or 1-year mortality, though it is associated with higher odds of blood transfusion and 30-day readmission.
Answers are grounded in this paper and cite their sources.
Perioperative antiplatelets show no mortality link; leaves open readmission and transfusion associations in observational hip fracture data.
Objectives: To assess whether perioperative antiplatelet use increases mortality risk among older adults undergoing operative hip fracture repair. Methods: Design: Retrospective study. Setting: Level 1 trauma center. Patient Selection Criteria: A total of 965 patients 65 years or older who underwent surgical fixation for hip fractures (OTA/OA 31A, 31B and 31C) between 2018 and 2023. Outcome Measures and Comparisons: The primary outcome was mortality at 365 days after discharge. Secondary outcomes were mortality at 30 days and 90 days, length of stay (LOS) > 7 days, need for blood transfusion, and 30-day readmission. Statistical Methods: Multivariate Cox proportional hazards models assessed the association between antiplatelet use and mortality. For secondary outcomes, a Firth penalized logistic regression model was used, correcting for potential confounders. RESULTS: The use of antiplatelet medications perioperatively was not significantly associated with mortality at 365 days, with adjusted hazard ratio (aHR) of 1.17, 95% confidence interval (CI) [0.76, 1.79] or at 30 days and 90 days, with aHRs of 0.94, 95% CI [0.44, 2.00] and 1.03, 95% CI [0.54, 1.97], respectively. There was a higher odds of being readmitted within 30 days of hospital discharge and getting a transfusion, with adjusted odds ratios (aORs) of 1.83, 95% CI [1.12, 3.00] and 1.60, 95% CI [1.00, 2.56], respectively, whereas there was no significant association with length of stay greater than 7 days, with aOR of 0.84, 95% CI [0.56, 1.26]. Conclusion: These findings indicate that undergoing hip fracture repair while on antiplatelet medications does not appear to confer a higher risk of mortality but may be correlated to higher readmission or transfusion rates. Level of Evidence: Therapeutic Level III.
No takes yet. Share an insight, caveat, or question.
Akodu et al. (2026) conducted a cohort in Operative hip fracture repair in older adults (n=965). Perioperative antiplatelet medication use (aspirin and/or clopidogrel) vs. No perioperative antiplatelet use was evaluated on Mortality at 365 days after hospital discharge (aHR 1.17, 95% CI 0.76, 1.79). Perioperative antiplatelet use was not associated with 365-day mortality in older adults undergoing operative hip fracture repair.
Synapse has enriched 10 related papers. Consider them for comparative context: